Essential thrombocythaemia and other myeloproliferative disorders with thrombocythaemia treated with Thromboreductin. A report from the database of Register for the 1st quarter of 2010

Abstract

In the Czech Republic, anagrelid is used according to the recommendations of the Czech Working Group on Myeloproliferative treatment of thrombocythaemia associated with chronic myeloproliferative disorders - mainly essential thrombocythaemia and, regularly, reports are being presented from the Register of patients treated with thromboreductin, most recently last year.

Keywords

• essential thrombocythaemia
• myeloproliferative disorders
• anagrelid (Thromboreductin)
• Register
• JAK2 mutation
• thrombophilia